Abstract
A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were significantly associated with increased overall survival.
MeSH terms
-
Adult
-
Aged
-
Brain Neoplasms / diagnosis*
-
Brain Neoplasms / radiotherapy*
-
DNA Methylation
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / therapeutic use
-
Glioblastoma / diagnosis*
-
Glioblastoma / radiotherapy*
-
Humans
-
Isocitrate Dehydrogenase / genetics
-
Medical Oncology / methods
-
Middle Aged
-
Mutation
-
O(6)-Methylguanine-DNA Methyltransferase / genetics
-
Prognosis
-
Promoter Regions, Genetic
-
Temozolomide
-
Treatment Outcome
Substances
-
Dacarbazine
-
Isocitrate Dehydrogenase
-
IDH1 protein, human
-
O(6)-Methylguanine-DNA Methyltransferase
-
Temozolomide